Innovative Therapies Centers of Excellence Act
SB 4031, the Innovative Therapies Centers of Excellence Act, would require the Department of Veterans Affairs to designate at least five VA medical facilities as centers of excellence for innovative therapies. The bill directs the Secretary of Veterans Affairs, acting on the recommendation of the Under Secretary for Health, to establish and operate these centers subject to appropriations, with an emphasis on geographic distribution across the country.
The centers would focus on research, education, and clinical use of specified “innovative therapies” for certain covered conditions. The bill defines covered conditions to include anxiety, bipolar disorder, chronic pain, depression, Parkinson’s disease, post-traumatic stress disorder, and substance use disorder, and it defines innovative therapies to include MDMA, 5-MeO-DMT, ibogaine, ketamine, psilocybin, and other therapies designated later by VA leadership. The bill also requires peer review of proposals, annual reporting to Congress, and the creation of a national data repository and broader provider consortium to spread access and knowledge throughout the VA system.
If enacted, the bill would amend title 38 of the U.S. Code by adding a new section requiring VA to create and manage a network of innovative therapies centers of excellence. It would impose new planning, staffing, reporting, and research obligations on the Department of Veterans Affairs, authorize $30 million annually for the centers’ research and education activities, and allow additional allocations from existing VA medical and research accounts. The bill would also shape how VA evaluates and expands access to psychedelic-assisted and other novel treatments for veterans, while leaving implementation details to the Under Secretary for Health.
Based on the bill text and available context, the overall sentiment appears supportive and forward-looking, with the measure framed as a research-and-access initiative for veterans’ mental health and chronic pain treatment. The bipartisan introduction by Senators Gallego and McCormick suggests cross-party interest in exploring innovative therapies within the VA. No votes or committee debate are available in the provided record, so there is no documented opposition or formal committee sentiment yet.
The main potential points of contention are likely to be the inclusion of psychedelic substances and other nontraditional therapies, the cost of establishing and operating multiple centers, and the need to ensure scientific and clinical rigor before wider adoption. The bill addresses some of these concerns by requiring peer review, limiting designation to proposals meeting the highest competitive standards, and tying operations to available appropriations. Another possible issue is how the VA will define and expand the list of covered conditions and therapies, since those categories can be broadened by the Under Secretary for Health.